InsiderSource

Novo Holdings A/S

10% Owner · SEC CIK 1388325
Insider at COAG Hemab Therapeutics Holdings, Inc. AVLN Avalyn Pharma Inc. MPLT MapLight Therapeutics, Inc. IOBT IO Biotech, Inc. SPRB SPRUCE BIOSCIENCES, INC. MGX Metagenomi, Inc. CYT Cyteir Therapeutics, Inc. IRON Disc Medicine, Inc. RPHM Reneo Pharmaceuticals, Inc. EWTX Edgewise Therapeutics, Inc. BOLT Bolt Biotherapeutics, Inc. CMPI Checkmate Pharmaceuticals, Inc. ACLX Arcellx, Inc. UTRS MINERVA SURGICAL INC VERV Verve Therapeutics, Inc. INGN Inogen Inc GRTX Galera Therapeutics, Inc. INZY Inozyme Pharma, Inc. GLTO Galecto, Inc. EAR Eargo, Inc. ALGS Aligos Therapeutics, Inc.
Advertisement

Buy track record

How this insider's open-market purchases have performed
50%
of buys now in profit
5 up · 5 down
Avg return since buy+38.7%
Median return−43.8%
Best trade+547.2%
Worst trade−100.0%
Buys scored10 (+7 n/a)
Average return by holding period — separates good entry timing from riding one long winner
After 1 month −1.9% 20% won · 10 trades
After 3 months −7.5% 22% won · 9 trades
After 6 months −14.2% 33% won · 9 trades
After 12 months −20.6% 38% won · 8 trades
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
May 1, 2026 AVLN $18 $10M +17% −10.7% — — — +0.8%
Oct 28, 2025 MPLT $17 $16.2M +35% −18.6% +12.6% +81.0% — +65.7%
Feb 13, 2024 MGX $15 $12M +85% −5.2% −44.0% −72.2% −79.0% −89.7%
Feb 9, 2024 MGX $10 $1.03M NEW +16.4% −33.2% −72.1% −76.4% −88.4%
Feb 16, 2023 SPRB $3 $7M +49% −8.8% −12.4% −11.6% +100.0% −99.6%
Sep 14, 2022 EWTX $10 $5M +8.7% −0.5% −22.7% −26.4% −35.7% +236.3%
Feb 8, 2022 ACLX $15 $12.5M +26% −3.6% −52.0% +9.9% +75.2% +547.2%
Oct 26, 2021 UTRS $12 $6.96M +39% −27.7% −49.0% −65.5% −95.7% −100.0%
Mar 30, 2021 EWTX $16 $10M +13% −8.3% −31.7% −46.8% −70.3% +12.8%
Oct 20, 2020 ALGS $15 $3M +8.3% +47.5% +164.7% +76.0% +17.7% −98.5%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 10 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$122.58M
17 trades
Open-market sells
$166.47M
38 trades
Net flow
−$43.89M
Net selling
Total filings
69
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
Advertisement
SPRB
SPRUCE BIOSCIENCES, INC.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Feb 21, 2023 ΔOwn +49%

Novo Holdings A/s, SPRB's 10% owner, spent $7M of their own money on 2.21M shares at $3, growing their stake 49%.

+$7M
2.21M sh @ $3
EWTX
Edgewise Therapeutics, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Sep 16, 2022 ΔOwn +8.7%

Novo Holdings A/s, EWTX's 10% owner, spent $5M of their own money on 484,496 shares at $10, growing their stake 9%.

+$5M
484,496 sh @ $10
CYT
Cyteir Therapeutics, Inc.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Jul 22, 2022 ΔOwn −19%

Novo Holdings A/s sold $2.7M of CYT, trimming their stake 19%.

−$2.7M
900,000 sh @ $3
ACLX
Arcellx, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Feb 9, 2022 ΔOwn +26%

Novo Holdings A/s, ACLX's 10% owner, spent $12.5M of their own money on 833,333 shares at $15, growing their stake 26%.

+$12.5M
833,333 sh @ $15
IOBT
IO Biotech, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Nov 10, 2021 ΔOwn +11%

Novo Holdings A/s, IOBT's 10% owner, spent $4.55M of their own money on 325,000 shares at $14, growing their stake 11%.

+$4.55M
325,000 sh @ $14
UTRS
MINERVA SURGICAL INC
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Oct 27, 2021 ΔOwn +39%

Novo Holdings A/s, UTRS's 10% owner, spent $6.96M of their own money on 580,000 shares at $12, growing their stake 39%.

+$6.96M
580,000 sh @ $12
CYT
Cyteir Therapeutics, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Jun 23, 2021 ΔOwn +6.1%

Novo Holdings A/s, CYT's 10% owner, spent $5M of their own money on 277,777 shares at $18, growing their stake 6%.

+$5M
277,777 sh @ $18
VERV
Verve Therapeutics, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Jun 22, 2021 ΔOwn +79%

Novo Holdings A/s, VERV's 10% owner, spent $6.65M of their own money on 350,000 shares at $19, growing their stake 79%.

+$6.65M
350,000 sh @ $19
INGN
Inogen Inc
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed Jun 3, 2021 ΔOwn −25%

Novo Holdings A/s sold $38.98M of INGN, trimming their stake 25%.

−$38.98M
680,000 sh @ $57
SPRB
SPRUCE BIOSCIENCES, INC.
Sell Novo Holdings A/S · 10% Owner · Open-market sale · filed May 21, 2021 ΔOwn −9.5%

Novo Holdings A/s sold $6.6M of SPRB, trimming their stake 10%.

−$6.6M
475,000 sh @ $14
RPHM
Reneo Pharmaceuticals, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Apr 14, 2021 ΔOwn +24%

Novo Holdings A/s, RPHM's 10% owner, spent $10M of their own money on 666,666 shares at $15, growing their stake 24%.

+$10M
666,666 sh @ $15
EWTX
Edgewise Therapeutics, Inc.
Buy Novo Holdings A/S · 10% Owner · Open-market purchase · filed Mar 31, 2021 ΔOwn +13%

Novo Holdings A/s, EWTX's 10% owner, spent $10M of their own money on 625,000 shares at $16, growing their stake 13%.

+$10M
625,000 sh @ $16

Frequently asked questions

How is Novo Holdings A/S's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Novo Holdings A/S's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.